|
WO2006113546A2
(en)
*
|
2005-04-15 |
2006-10-26 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
WO2009020923A1
(en)
*
|
2007-08-03 |
2009-02-12 |
Musc Foundation For Research Development |
Human monoclonal antibodies and methods for producing the same
|
|
WO2009062050A2
(en)
|
2007-11-08 |
2009-05-14 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Ｐｃｓｋ９拮抗劑類
|
|
US8725420B2
(en)
*
|
2008-10-31 |
2014-05-13 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US9060926B2
(en)
*
|
2008-10-31 |
2015-06-23 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8731841B2
(en)
|
2008-10-31 |
2014-05-20 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8721583B2
(en)
*
|
2008-10-31 |
2014-05-13 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US20100111836A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US9050317B2
(en)
*
|
2008-10-31 |
2015-06-09 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US20100111835A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8409376B2
(en)
|
2008-10-31 |
2013-04-02 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US20100111857A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Boyden Edward S |
Compositions and methods for surface abrasion with frozen particles
|
|
US8849441B2
(en)
|
2008-10-31 |
2014-09-30 |
The Invention Science Fund I, Llc |
Systems, devices, and methods for making or administering frozen particles
|
|
US9050070B2
(en)
*
|
2008-10-31 |
2015-06-09 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US20100111841A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US9060931B2
(en)
*
|
2008-10-31 |
2015-06-23 |
The Invention Science Fund I, Llc |
Compositions and methods for delivery of frozen particle adhesives
|
|
US20100111831A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for surface abrasion with frozen particles
|
|
US8603494B2
(en)
*
|
2008-10-31 |
2013-12-10 |
The Invention Science Fund I, Llc |
Compositions and methods for administering compartmentalized frozen particles
|
|
US8545857B2
(en)
*
|
2008-10-31 |
2013-10-01 |
The Invention Science Fund I, Llc |
Compositions and methods for administering compartmentalized frozen particles
|
|
US8793075B2
(en)
*
|
2008-10-31 |
2014-07-29 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8551505B2
(en)
*
|
2008-10-31 |
2013-10-08 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8545855B2
(en)
*
|
2008-10-31 |
2013-10-01 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US9072688B2
(en)
|
2008-10-31 |
2015-07-07 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US9072799B2
(en)
|
2008-10-31 |
2015-07-07 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US8858912B2
(en)
*
|
2008-10-31 |
2014-10-14 |
The Invention Science Fund I, Llc |
Frozen compositions and methods for piercing a substrate
|
|
US8603495B2
(en)
*
|
2008-10-31 |
2013-12-10 |
The Invention Science Fund I, Llc |
Compositions and methods for biological remodeling with frozen particle compositions
|
|
US8788211B2
(en)
*
|
2008-10-31 |
2014-07-22 |
The Invention Science Fund I, Llc |
Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
|
|
US8731840B2
(en)
|
2008-10-31 |
2014-05-20 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8545806B2
(en)
*
|
2008-10-31 |
2013-10-01 |
The Invention Science Fund I, Llc |
Compositions and methods for biological remodeling with frozen particle compositions
|
|
US8762067B2
(en)
|
2008-10-31 |
2014-06-24 |
The Invention Science Fund I, Llc |
Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
|
|
US9050251B2
(en)
*
|
2008-10-31 |
2015-06-09 |
The Invention Science Fund I, Llc |
Compositions and methods for delivery of frozen particle adhesives
|
|
US9060934B2
(en)
*
|
2008-10-31 |
2015-06-23 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US20100111834A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for therapeutic delivery with frozen particles
|
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
|
AR080291A1
(es)
|
2010-02-24 |
2012-03-28 |
Rinat Neuroscience Corp |
Anticuerpos antagonistas anti receptor de il-7 y procedimientos
|
|
NZ602220A
(en)
|
2010-03-11 |
2014-10-31 |
Rinat Neuroscience Corp |
Antibodies with ph dependent antigen binding
|
|
CA2803391C
(en)
*
|
2010-06-22 |
2021-11-09 |
Neogenix Oncology, Inc. |
Npc1 antibodies that bind a muc5ac epitope
|
|
EP2622091B1
(en)
|
2010-09-23 |
2019-03-13 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
|
RU2014123030A
(ru)
|
2011-12-22 |
2016-02-20 |
Ринат Ньюросайенс Корп. |
Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
|
|
RU2015115956A
(ru)
|
2012-11-09 |
2017-01-10 |
Пфайзер Инк. |
Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
|
|
EP3336104A1
(en)
|
2012-12-28 |
2018-06-20 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
|
CN105189560A
(zh)
|
2013-05-07 |
2015-12-23 |
瑞纳神经科学公司 |
抗胰高血糖素受体抗体和其使用方法
|
|
MX371455B
(es)
|
2013-08-02 |
2020-01-28 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
|
|
CN105814081B
(zh)
|
2013-11-13 |
2021-02-02 |
辉瑞大药厂 |
肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
SMT202100146T1
(it)
|
2014-04-30 |
2021-05-07 |
Pfizer |
Coniugati di anticorpo anti-ptk7-farmaco
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
|
HUE057285T2
(hu)
|
2015-04-13 |
2022-04-28 |
Pfizer |
Terápiás ellenanyagok és alkalmazásaik
|
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
|
EP3365369A1
(en)
|
2015-10-23 |
2018-08-29 |
Pfizer Inc |
Anti-il-2 antibodies and compositions and uses thereof
|
|
ES2904593T3
(es)
|
2016-01-21 |
2022-04-05 |
Pfizer |
Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
|
|
IL310865A
(en)
|
2016-10-17 |
2024-04-01 |
Pfizer |
Antibodies against EDB and antibody-drug conjugates
|
|
WO2018156791A1
(en)
*
|
2017-02-22 |
2018-08-30 |
Aleta Biotherapeutics Inc. |
Compositions and methods for tumor transduction
|
|
US11198735B2
(en)
|
2017-03-03 |
2021-12-14 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
|
JP7234142B2
(ja)
|
2017-06-02 |
2023-03-07 |
ファイザー・インク |
Ｆｌｔ３に特異的な抗体およびその使用
|
|
SG11202006945PA
(en)
|
2018-01-26 |
2020-08-28 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
HRP20251184T1
(hr)
|
2018-01-26 |
2025-12-05 |
Exelixis, Inc. |
Spojevi za liječenje poremećaja ovisnih o kinazi
|
|
AU2019212800B2
(en)
|
2018-01-26 |
2024-05-23 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
|
MX2020008183A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos.
|
|
JP7555270B2
(ja)
|
2018-02-13 |
2024-09-24 |
プレシジョン バイオロジックス、インコーポレイテッド |
Ｔｒｅｇ細胞を標的とするための方法及び組成物
|
|
MX387358B
(es)
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
|
PL3894012T4
(pl)
|
2018-12-13 |
2026-01-05 |
Exelixis, Inc. |
Postacie krystaliczne i postacie soli inhibitora kinazy
|
|
EP3914356A1
(en)
|
2019-01-25 |
2021-12-01 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
|
EP3927430A1
(en)
|
2019-02-18 |
2021-12-29 |
Pfizer Inc. |
Method of treatment of chronic low back pain
|
|
WO2020215037A1
(en)
|
2019-04-18 |
2020-10-22 |
The Regents Of The University Of Michigan |
Combination with checkpoint inhibitors to treat cancer
|
|
KR102826380B1
(ko)
|
2019-06-03 |
2025-06-26 |
엑셀리시스, 인코포레이티드 |
카이네이스 저해제의 결정질 염 형태
|
|
AR119069A1
(es)
|
2019-06-04 |
2021-11-24 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de quinasas
|
|
EP4118105A2
(en)
|
2020-03-09 |
2023-01-18 |
Pfizer Inc. |
Cd80-fc fusion protein and uses thereof
|
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
|
EP4171632A2
(en)
|
2020-06-26 |
2023-05-03 |
Pfizer Inc. |
Methods of treating inflammatory bowel disease with tl1a antibodies
|
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
|
US20230314440A1
(en)
|
2020-08-21 |
2023-10-05 |
Exelixis, Inc. |
Method of treating cancer
|
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
|
AU2022420610A1
(en)
|
2021-12-22 |
2024-06-27 |
Exelixis, Inc. |
Crystalline forms and salt forms of a kinase inhibitor
|
|
IL315262A
(en)
|
2022-03-03 |
2024-10-01 |
Pfizer |
Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
WO2023218320A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Anti-lymphotoxin beta receptor antibodies and methods of use thereof
|
|
IL316894A
(en)
|
2022-05-26 |
2025-01-01 |
Pfizer |
ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2023233330A1
(en)
|
2022-05-31 |
2023-12-07 |
Pfizer Inc. |
Anti-bmp9 antibodies and methods of use thereof
|
|
CN120035602A
(zh)
|
2022-06-17 |
2025-05-23 |
辉瑞公司 |
Il-12变体、抗-pd1抗体、融合蛋白及其用途
|
|
US20240052047A1
(en)
|
2022-08-03 |
2024-02-15 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|
|
EP4590699A1
(en)
|
2022-09-22 |
2025-07-30 |
Pfizer Inc. |
Methods of treatment with ifn-beta antibodies
|
|
CN120548194A
(zh)
|
2023-01-18 |
2025-08-26 |
辉瑞公司 |
针对呼吸道疾病的疫苗
|
|
WO2024218650A1
(en)
|
2023-04-19 |
2024-10-24 |
Pfizer Inc. |
Lilrb1 and lilrb2 antibodies and methods of use thereof
|
|
AU2024273758A1
(en)
|
2023-05-17 |
2025-12-04 |
Genentech, Inc. |
Anti-tl1a antibody therapeutic methods
|
|
CN121443322A
(zh)
|
2023-07-03 |
2026-01-30 |
施慧达药业集团(吉林)有限公司 |
蛋白质异二聚体的治疗用途
|
|
IL328096A
(en)
|
2023-11-10 |
2026-06-01 |
Pfizer |
Anti-migis-alpha antibodies and methods of use thereof
|
|
US20250163168A1
(en)
|
2023-11-17 |
2025-05-22 |
Pfizer Inc. |
Novel antibodies and antibody conjugates for the treatment of metabolic disorders
|
|
WO2025257715A1
(en)
|
2024-06-12 |
2025-12-18 |
Seagen Inc. |
Anti-ceacam5 antibodies, antibody-drug conjugates and methods of uses thereof
|
|
WO2026117626A1
(en)
*
|
2024-11-27 |
2026-06-04 |
Disc Medicine, Inc. |
Antibody compositions and uses thereof
|